Endo touts successful Phase III in cancer pain
Endo Therapeutics' late-stage trial for Rapinyl, a cancer pain therapy, demonstrated that the therapy was highly effective, hitting all primary and secondary goals. The biotech said the trial was so successful--relieving cancer pain for a statistically significant group within 30 minutes--that it may go ahead with an application for marketing approval even as it recruits patients for another Phase III trial. The side effects of the drug were in line with other opioids. That's all good news for Orexo AB, which licensed the therapy to Endo.
"We remain confident that Rapinyl's quick dissolution and rapid absorption profile make it a potentially attractive treatment for breakthrough cancer pain," said David A. Lee, M.D., Ph.D., the company's CSO.
- check out the release for more info
Related Articles:
Endo plans for the future. Report
Endo, Vernalis get FDA rejection for Frova. Report
Endo shares up on positive painkiller data. Report
Be the first to comment Rate it:
Comments
Post new comment
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends